Unadjusted and adjusted hazard ratios across categories of baseline CD4 cell count in Zambia and Switzerland.

<p>Results for loss to follow-up from the subdistribution competing risk model and for loss to follow-up and death from standard Cox models are shown.</p><p>HR: hazard ratio; sHR: subdistribution hazard ratio; CI: confidence interval.</p><p>*Adjusted for age, gender, disease stage and body mass index.</p

Baseline characteristics and mortality at end of follow-up among patients starting antiretroviral therapy in two cohorts in Zambia and Switzerland.

<p>CIDRZ: Centre for Infectious Disease Research in Zambia; SHCS: Swiss HIV Cohort Study; IQR: interquartile range; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz; ETC: emtricitabine; TNV: tenofovir; LPV: lopinavir.</p><p>*Advanced: WHO stage III/IV or CDC clinical stage C.</p

Standard Kaplan-Meier (KM) curves and cumulative incidence curves from competing risk (CR) analyses of loss to follow-up and death in the CIDRZ cohort in Zambia and the Swiss HIV Cohort Study.

<p>Standard Kaplan-Meier (KM) curves and cumulative incidence curves from competing risk (CR) analyses of loss to follow-up and death in the CIDRZ cohort in Zambia and the Swiss HIV Cohort Study.</p

Health facility quality scores and correlation with PMTCT coverage, PEARL Facility Survey, 2007–2009.

<p>ρ: Pearson correlation coefficient, IQR: Interquartile range.</p><p>*p-value for univariate regression models treating coverage as a continuous measure, using GEE to account for correlation due to clustering of facilities within countries.</p

Health facility characteristics by country; PEARL Facility Survey, 2007–2009.

£<p>: <b>Note that this item is not related to HIV, but to maternal and infant health in general.</b></p><p>*Survey was conducted in delivery facilities where antenatal activities are implemented.</p><p>IQR: Interquartile range.</p

Relationship between composite ANC score and PMTCT coverage.

<p>PEARL Facility Survey, 2007–2009.</p

Antenatal care service provision among observed patients, by country; PEARL Facility Survey, 2007–2009^†.

<p>CBS: Cord blood specimens, IQR: Interquartile range, std: standard deviation.</p><p>**full coverage defined as the proportion of HIV-exposed infants in the sample with both maternal nevirapine ingestion (confirmed by cord blood chromatography) and infant nevirapine ingestion (confirmed by direct observation).</p>†<p>For the direct observation patient measures we first calculated the percent observed at each facility among the up to 6 cases and then computed <u>the mean (and standard deviation)</u> of those facility-level percents to get the overall country values shown in the table.</p

Relationship among service coverage at the facility level, service coverage at the community level, and HIV-free survival in children under 2 y of age in the PEARL Study.

<p>(A) Facility-based coverage versus community-based coverage; (B) community-based coverage versus HIV-free survival; (C) facility-based coverage versus HIV-free survival.</p

Flow chart of patients included in virological analyses.

<p>(HBV: hepatitis B virus; VL: viral load)</p

Baseline HBV drug resistance mutations,

<p>Baseline HBV drug resistance mutations,</p